创新国信，成立于2019年，是国信医药的全资子公司。专注于为全球生物医药企业提供全方位、一体化的I期-IV期的临床研发服务。我们承诺基于系统和数字化运用的高效能团队执行，全力推进研究项目的进度达成；承诺基于ICH/Transcelerate符合行业标准的临床质量管理体系，对所有客户的临床试验受试者和研究数据提供质量保证。

融入全球化、创新再出发! 创新国信临床研究团队是一个立足中国、面向全球的科技型全功能数字化运营临床研究团队，主要承接肿瘤治疗、细胞治疗、基因治疗等方向的创新药临床研究，提供一站式综合性专业技术服务与解决方案，协助客户提高临床研发效率、降低研发成本、缩短研发周期、提高研发成功几率，助力新药快速上市，创造社会价值 ！
GX INNOV, established in 2019, is a wholly-owned subsidiary of GX pharma, focusing on providing full range and integrated clinical R&D services from phase 1 to phase 4 to global biomedical enterprises. We promise efficient team execution based on application of system and digitalization, and spare no efforts to promote the progress of research projects. We are committed to provide quality assurance for clinical trial subjects and research data of all clients based on ICH/Transccelerate clinical trial quality management system conforming to industry standards.

Integrated into globalization and innovation, GX INNOV, basing China and facing the world, has an all-around scientific and technological digital clinical operation team. It mainly undertakes tumor therapy, cell therapy and gene therapy trials, etc., provides one-stop comprehensive professional technical services and solutions, supports customers to improve efficiency, reduce cost, shorten lifecycle and increase the success probability of clinical R & D, speeds up new drugs to markets and creates social value.